Factors associated with infection amongst paediatric patients with systemic lupus erythematosus treated in the intensive care unit.


Journal

Lupus
ISSN: 1477-0962
Titre abrégé: Lupus
Pays: England
ID NLM: 9204265

Informations de publication

Date de publication:
Aug 2019
Historique:
pubmed: 2 7 2019
medline: 16 1 2020
entrez: 2 7 2019
Statut: ppublish

Résumé

To identify determinants and outcomes associated with infection in paediatric systemic lupus erythematosus (SLE) patients at admission and during hospitalization in intensive care units (ICUs). A retrospective cohort study of paediatric SLE patients admitted to two ICUs was conducted. Frequency and risk factors of infection as well as mortality were studied. Seventy-three infection episodes amongst 55 patients were analysed. The median age was 14.4 years (IQR 12.5-16). The median SLEDAI was 16 (IQR 12-20). Twenty-nine episodes were documented at admission; the CRP was higher in these patients (6.58 versus 1.04 mg/dl, p<0.001) than in non-infected patients, even after multivariate adjustment (OR 8.6, 95% CI = 2.1-34.8, p = 0.003). Twenty-five (34.7%) episodes occurred during hospitalization. Lupus activity (OR 1.14, 95% CI = 1.01-1.27, p = 0.029), cyclophosphamide (OR 17.9, 95% CI = 2-156, p = 0.009) and mechanical ventilation (OR 16, 95% CI = 2.1-122, p = 0.008) were associated with infection. Ten episodes (14%) led to death. Admission to the ICU due to infection was strongly associated with mortality (90% versus 31.8%, OR 19.4, 95% CI = 2.3-163, p = 0.006). In paediatric lupus patients admitted to the ICU, elevated CRP should alert clinicians to possible infection. During hospitalization, SLE activity and cyclophosphamide were associated with infection. Infection at admission to the ICU was strongly associated with mortality.

Identifiants

pubmed: 31256746
doi: 10.1177/0961203319860194
doi:

Substances chimiques

Immunosuppressive Agents 0
Cyclophosphamide 8N3DW7272P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1141-1147

Auteurs

M Restrepo-Escobar (M)

1 University of Antioquia, Medellín, Colombia.
2 Pablo Tobón Uribe Hospital, Medellín, Colombia.

N A Ríos (N)

1 University of Antioquia, Medellín, Colombia.

L J Hernández-Zapata (LJ)

1 University of Antioquia, Medellín, Colombia.

M Velásquez (M)

3 San Vicente Fundación University Hospital, Medellín, Colombia.

R Eraso (R)

1 University of Antioquia, Medellín, Colombia.
2 Pablo Tobón Uribe Hospital, Medellín, Colombia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH